IN2014MN01998A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01998A IN2014MN01998A IN1998MUN2014A IN2014MN01998A IN 2014MN01998 A IN2014MN01998 A IN 2014MN01998A IN 1998MUN2014 A IN1998MUN2014 A IN 1998MUN2014A IN 2014MN01998 A IN2014MN01998 A IN 2014MN01998A
- Authority
- IN
- India
- Prior art keywords
- particulate
- metal salts
- ynamide
- dihydroquinazolin
- pyrazolo
- Prior art date
Links
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical class CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- DRXWSHCGSIJSID-UHFFFAOYSA-N hex-5-ynamide Chemical compound NC(=O)CCCC#C DRXWSHCGSIJSID-UHFFFAOYSA-N 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 229940071138 stearyl fumarate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
There is provided inter alia a dry powder pharmaceutical formulation for inhalation comprising: (i) 6 (2 ((4 amino 3 (3 hydroxyphenyl) 1 H pyrazolo[3 4 d]pyrimidin 1 yl) methyl) 3 (2 chlorobenzyl) 4 oxo 3 4 dihydroquinazolin 5 yl) N N bis(2 methoxyethyl)hex 5 ynamide or a pharmaceutically acceptable salt thereof including all stereoisomers tautomers and isotopic derivatives thereof and solvates thereof in particulate form as active ingredient; (ii) particulate lactose as carrier; and (iii) a particulate stabilizing agent selected from metal salts of stearic acid such as magnesium stearate and metal salts of stearyl fumarate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610023P | 2012-03-13 | 2012-03-13 | |
| US201261610012P | 2012-03-13 | 2012-03-13 | |
| PCT/GB2013/050623 WO2013136075A1 (en) | 2012-03-13 | 2013-03-13 | Novel pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01998A true IN2014MN01998A (en) | 2015-08-14 |
Family
ID=49160309
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1998MUN2014 IN2014MN01998A (en) | 2012-03-13 | 2013-03-13 | |
| IN2000MUN2014 IN2014MN02000A (en) | 2012-03-13 | 2013-03-13 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2000MUN2014 IN2014MN02000A (en) | 2012-03-13 | 2013-03-13 |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20150099768A1 (en) |
| EP (2) | EP2825202B1 (en) |
| JP (3) | JP2015509973A (en) |
| KR (2) | KR20140131971A (en) |
| CN (2) | CN104284679B (en) |
| AU (2) | AU2013234081B2 (en) |
| CA (2) | CA2864643A1 (en) |
| CL (2) | CL2014002385A1 (en) |
| CO (2) | CO7061079A2 (en) |
| CR (2) | CR20140417A (en) |
| CY (1) | CY1118565T1 (en) |
| DK (1) | DK2834244T3 (en) |
| EA (2) | EA025465B1 (en) |
| EC (2) | ECSP14018142A (en) |
| ES (2) | ES2600705T3 (en) |
| GT (2) | GT201400182A (en) |
| HR (1) | HRP20161383T1 (en) |
| HU (1) | HUE029420T2 (en) |
| IL (2) | IL233886A (en) |
| IN (2) | IN2014MN01998A (en) |
| LT (1) | LT2834244T (en) |
| MX (2) | MX357170B (en) |
| MY (1) | MY171125A (en) |
| NI (2) | NI201400101A (en) |
| NZ (2) | NZ627963A (en) |
| PE (2) | PE20141964A1 (en) |
| PH (2) | PH12014501713A1 (en) |
| PL (1) | PL2834244T3 (en) |
| PT (1) | PT2834244T (en) |
| SG (2) | SG11201404522VA (en) |
| SI (1) | SI2834244T1 (en) |
| TW (2) | TWI617561B (en) |
| UA (1) | UA115544C2 (en) |
| WO (2) | WO2013136075A1 (en) |
| ZA (2) | ZA201407374B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| UY33337A (en) | 2010-10-18 | 2011-10-31 | Respivert Ltd | SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES |
| UA115544C2 (en) | 2012-03-13 | 2017-11-27 | Респіверт Лімітед | Novel pharvaceutical formulations |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| TW201522341A (en) | 2013-03-15 | 2015-06-16 | Respivert Ltd | Compound |
| US9227977B2 (en) | 2013-03-15 | 2016-01-05 | Respivert Ltd. | Phosphoinositide 3-kinase inhibitors |
| PT3052485T (en) | 2013-10-04 | 2021-10-22 | Infinity Pharmaceuticals Inc | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MX382033B (en) | 2014-03-19 | 2025-03-13 | Infinity Pharmaceuticals Inc | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA-MEDIATED DISORDERS. |
| HK1232227A1 (en) | 2014-07-04 | 2018-01-05 | Lupin Limited | Quinolizinone derivatives as pi3k inhibitors |
| EA201692456A1 (en) * | 2014-07-09 | 2017-08-31 | Арвен Иладж Санайи Ве Тиджарет А.Ш. | METHOD OF OBTAINING COMPOSITIONS FOR INHALATION |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| SG11201809042SA (en) | 2016-04-15 | 2018-11-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1204826B (en) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | INHALATION PHARMACEUTICAL COMPOSITIONS |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| WO1999028979A2 (en) | 1997-12-02 | 1999-06-10 | Alcatel Usa Sourcing, L.P. | Digital phone system |
| PL200941B1 (en) | 1998-11-13 | 2009-02-27 | Jagotec Ag | Dry powder for inhalation |
| US6383790B1 (en) | 1999-01-11 | 2002-05-07 | Princeton University | High affinity protein kinase inhibitors |
| ATE363892T1 (en) | 1999-03-05 | 2007-06-15 | Chiesi Farma Spa | IMPROVED POWDER FORMULATIONS FOR INHALATION |
| PE20011227A1 (en) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| KR100774855B1 (en) | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | Condensed heteroaryl derivatives |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| WO2003006628A2 (en) | 2001-07-13 | 2003-01-23 | Virtual Drug Development, Inc. | Nad synthetase inhibitors and uses thereof |
| AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| WO2004037176A2 (en) | 2002-10-21 | 2004-05-06 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
| RU2366655C2 (en) | 2003-03-14 | 2009-09-10 | Оно Фармасьютикал Ко., Лтд. | Nitrogen-containing heterocyclic derivatives and medicaments thereof as active ingredient |
| US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
| JP2007524605A (en) | 2003-04-03 | 2007-08-30 | ピーディーエル バイオファーマ，インコーポレイティド | Inhibitors of integrin α5β1 and their use for control of tissue granulation |
| US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| GB0316341D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulations |
| EP1643973A1 (en) | 2003-07-11 | 2006-04-12 | Glaxo Group Limited | Pharmaceutical formulations comprising magnesium stearate |
| JPWO2005012221A1 (en) | 2003-08-04 | 2006-09-14 | 小野薬品工業株式会社 | Diphenyl ether compound, its production method and use |
| US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
| WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
| GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| CA2552664A1 (en) | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
| CA2566436C (en) | 2004-05-13 | 2011-05-10 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| WO2005113556A1 (en) * | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| WO2005117889A1 (en) | 2004-05-25 | 2005-12-15 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic |
| EP1750715A1 (en) | 2004-06-04 | 2007-02-14 | Icos Corporation | Methods for treating mast cell disorders |
| US8143404B2 (en) | 2004-09-13 | 2012-03-27 | Ono Pharmaceutical Co., Ltd | Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| WO2006089106A2 (en) | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
| GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
| SI2004654T1 (en) | 2006-04-04 | 2013-11-29 | The Regents Of The University Of California | Pyrazolopyrimidine derivatives for use as kinase antagonists |
| WO2007114926A2 (en) | 2006-04-04 | 2007-10-11 | The Regents Of The University Of California | Kinase antagonists |
| EA200802348A1 (en) | 2006-05-24 | 2009-08-28 | Байер Шеринг Фарма Акциенгезельшафт | HUMAN HIGH-AFFINNE AND HUMANIZED ANTI-α5β1 INTEGRIN WITH A FUNCTION OF A BLOCKING ANTIBODY WITH A WEAKENED IMMUNOGENICITY |
| CA2655720A1 (en) | 2006-06-29 | 2008-01-10 | Schering Corporation | Substituted bicyclic and tricyclic thrombin receptor antagonists |
| GB0622818D0 (en) | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
| CA2668744C (en) | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| WO2008067219A2 (en) | 2006-11-29 | 2008-06-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| EP2137158A4 (en) | 2007-02-28 | 2012-04-18 | Methylgene Inc | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
| AR066477A1 (en) * | 2007-05-09 | 2009-08-19 | Novartis Ag | IMIDAZOPIRIDAZINAS REPLACED AS INHIBITORS OF CINASA DE LIPIDO |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| MX2010007419A (en) | 2008-01-04 | 2010-11-12 | Intellikine Inc | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS. |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| WO2010059593A1 (en) | 2008-11-18 | 2010-05-27 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
| WO2010065923A2 (en) | 2008-12-04 | 2010-06-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
| US8658648B2 (en) | 2008-12-05 | 2014-02-25 | Designmedix, Inc. | Modified chloroquines with single ring moiety or fused ring moiety |
| US20110135655A1 (en) | 2009-01-13 | 2011-06-09 | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication |
| BRPI1012333A2 (en) | 2009-03-24 | 2016-03-29 | Gilead Calistoga Llc | atropisomers of 2-purinyl-3-tolyl-quinazolinones derivatives and methods of use |
| SG178106A1 (en) | 2009-08-05 | 2012-03-29 | Versitech Ltd | Antiviral compounds and methods of making and using thereof |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| WO2011083387A1 (en) | 2010-01-07 | 2011-07-14 | Pfizer Limited | Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester |
| CN201676365U (en) | 2010-03-29 | 2010-12-22 | 山东京卫制药有限公司 | Drug administration device with voice prompt function |
| CN201692450U (en) | 2010-06-22 | 2011-01-05 | 于清 | High-efficiency dry powder sucker for drug delivery |
| AU2011298315B2 (en) | 2010-08-31 | 2014-08-28 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
| RU2580890C2 (en) | 2010-09-30 | 2016-04-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Using magnesium stearate in dry inhalation powder formulations |
| UY33337A (en) | 2010-10-18 | 2011-10-31 | Respivert Ltd | SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES |
| CN202154919U (en) | 2011-05-03 | 2012-03-07 | 王晓明 | Anti-cross-infection aerosol inhalation device |
| UA115544C2 (en) | 2012-03-13 | 2017-11-27 | Респіверт Лімітед | Novel pharvaceutical formulations |
-
2013
- 2013-03-13 UA UAA201408662A patent/UA115544C2/en unknown
- 2013-03-13 CN CN201380013848.1A patent/CN104284679B/en not_active Expired - Fee Related
- 2013-03-13 TW TW102108767A patent/TWI617561B/en not_active IP Right Cessation
- 2013-03-13 NZ NZ627963A patent/NZ627963A/en not_active IP Right Cessation
- 2013-03-13 CN CN201380013851.3A patent/CN104302650B/en not_active Expired - Fee Related
- 2013-03-13 EA EA201491674A patent/EA025465B1/en not_active IP Right Cessation
- 2013-03-13 EA EA201491675A patent/EA023715B1/en not_active IP Right Cessation
- 2013-03-13 EP EP13711104.3A patent/EP2825202B1/en active Active
- 2013-03-13 LT LTEP13711105.0T patent/LT2834244T/en unknown
- 2013-03-13 AU AU2013234081A patent/AU2013234081B2/en not_active Ceased
- 2013-03-13 KR KR1020147026305A patent/KR20140131971A/en not_active Ceased
- 2013-03-13 NZ NZ628072A patent/NZ628072A/en not_active IP Right Cessation
- 2013-03-13 WO PCT/GB2013/050623 patent/WO2013136075A1/en not_active Ceased
- 2013-03-13 MX MX2014010990A patent/MX357170B/en active IP Right Grant
- 2013-03-13 JP JP2014561515A patent/JP2015509973A/en active Pending
- 2013-03-13 US US14/381,273 patent/US20150099768A1/en not_active Abandoned
- 2013-03-13 DK DK13711105.0T patent/DK2834244T3/en active
- 2013-03-13 PE PE2014001414A patent/PE20141964A1/en not_active Application Discontinuation
- 2013-03-13 US US14/381,289 patent/US9642799B2/en not_active Expired - Fee Related
- 2013-03-13 CA CA 2864643 patent/CA2864643A1/en not_active Abandoned
- 2013-03-13 IN IN1998MUN2014 patent/IN2014MN01998A/en unknown
- 2013-03-13 HU HUE13711105A patent/HUE029420T2/en unknown
- 2013-03-13 PT PT137111050T patent/PT2834244T/en unknown
- 2013-03-13 IN IN2000MUN2014 patent/IN2014MN02000A/en unknown
- 2013-03-13 WO PCT/GB2013/050624 patent/WO2013136076A1/en not_active Ceased
- 2013-03-13 ES ES13711105.0T patent/ES2600705T3/en active Active
- 2013-03-13 TW TW102108766A patent/TWI586378B/en not_active IP Right Cessation
- 2013-03-13 HR HRP20161383TT patent/HRP20161383T1/en unknown
- 2013-03-13 SI SI201330362A patent/SI2834244T1/en unknown
- 2013-03-13 EP EP13711105.0A patent/EP2834244B1/en active Active
- 2013-03-13 JP JP2014561514A patent/JP6189874B2/en not_active Expired - Fee Related
- 2013-03-13 MX MX2014010991A patent/MX355299B/en active IP Right Grant
- 2013-03-13 CA CA 2864652 patent/CA2864652A1/en not_active Abandoned
- 2013-03-13 AU AU2013234080A patent/AU2013234080B2/en not_active Ceased
- 2013-03-13 SG SG11201404522VA patent/SG11201404522VA/en unknown
- 2013-03-13 PE PE2014001415A patent/PE20142342A1/en not_active Application Discontinuation
- 2013-03-13 SG SG11201404519UA patent/SG11201404519UA/en unknown
- 2013-03-13 KR KR1020147026258A patent/KR20140141596A/en not_active Ceased
- 2013-03-13 MY MYPI2014702576A patent/MY171125A/en unknown
- 2013-03-13 ES ES13711104.3T patent/ES2650791T3/en active Active
- 2013-03-13 PL PL13711105T patent/PL2834244T3/en unknown
-
2014
- 2014-07-30 PH PH12014501713A patent/PH12014501713A1/en unknown
- 2014-07-30 IL IL233886A patent/IL233886A/en not_active IP Right Cessation
- 2014-07-30 IL IL233883A patent/IL233883A0/en unknown
- 2014-08-27 PH PH12014501922A patent/PH12014501922A1/en unknown
- 2014-08-29 CO CO14190112A patent/CO7061079A2/en unknown
- 2014-08-29 CO CO14190111A patent/CO7051030A2/en unknown
- 2014-09-01 GT GT201400182A patent/GT201400182A/en unknown
- 2014-09-02 GT GT201400183A patent/GT201400183A/en unknown
- 2014-09-05 NI NI201400101A patent/NI201400101A/en unknown
- 2014-09-05 NI NI201400100A patent/NI201400100A/en unknown
- 2014-09-09 CL CL2014002385A patent/CL2014002385A1/en unknown
- 2014-09-09 CL CL2014002386A patent/CL2014002386A1/en unknown
- 2014-09-10 CR CR20140417A patent/CR20140417A/en unknown
- 2014-09-10 CR CR20140416A patent/CR20140416A/en unknown
- 2014-09-10 EC ECIEPI201418142A patent/ECSP14018142A/en unknown
- 2014-09-12 EC ECIEPI201418630A patent/ECSP14018630A/en unknown
- 2014-10-10 ZA ZA2014/07374A patent/ZA201407374B/en unknown
- 2014-10-10 ZA ZA2014/07373A patent/ZA201407373B/en unknown
-
2016
- 2016-11-09 CY CY20161101148T patent/CY1118565T1/en unknown
-
2017
- 2017-05-08 US US15/588,845 patent/US20170239256A1/en not_active Abandoned
- 2017-08-04 JP JP2017151378A patent/JP2018008992A/en not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01998A (en) | ||
| NZ629442A (en) | Heterocyclyl compounds as mek inhibitors | |
| JP2013538214A5 (en) | ||
| TN2012000544A1 (en) | Soluble guanylate cyclase activators | |
| NZ604345A (en) | Pyrazolo[1,5-a]pyrimidines as antiviral agents | |
| MX378495B (en) | Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | |
| NZ630457A (en) | Compounds useful as inhibitors of atr kinase | |
| MY158193A (en) | Morpholino pyrimidines and their use in therapy | |
| MX2015010971A (en) | Novel pyrazole derivative. | |
| JP2015509972A5 (en) | ||
| MY196072A (en) | Liquid Inhalation Formulation Comprising RPL554 | |
| RU2017134002A (en) | STABLE TETRAHYDROBIOPTERIN COMPOSITIONS | |
| IN2014DN01619A (en) | ||
| MX2016012669A (en) | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZ OLE DERIVATIVES AS ROS1 INHIBITORS. | |
| MX339685B (en) | New (trimethoxyphenylamino)pyrimidinyl formulations. | |
| PH12020552236A1 (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| IN2014MN02156A (en) | ||
| IN2014CN02850A (en) | ||
| CA3010857A1 (en) | Pharmaceutical composition comprising nebivolol with improved dissolution rate | |
| HRP20200472T1 (en) | TREATMENT OF ALOPECIA AREATE | |
| UA93355C2 (en) | Formulation of suberoylanilide hydroxamic acid and method for producing same | |
| MY144613A (en) | Formulations of suberoylanilide hydroxamic acid and methods for producing same | |
| TH156275A (en) | New pharmaceutical formulation | |
| WO2012093404A8 (en) | Parenteral formulations of levosimendan | |
| MX2025010806A (en) | Topical pharmaceutical formulation comprising kinase inhibitor |